May 13 2011
Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and other pharmaceuticals today announced that TPI has received the China's SFDA's approval for its anti-diabetic drug Gliclazide Tablets (80 mg formulation).
Gliclazide is an oral anti-diabetic drug that is used for the control of hyperglycemia in gliclazide-response diabetes mellitus of stable, mild, non-ketosis prone, maturity-onset. It is used when diabetes could not be managed by proper dietary adjustment and exercise or when not suitable for insulin therapy.
TPI is anticipating that its Gliclazide Tablets to make its market entry in July this year.
SOURCE Tianyin Pharmaceutical Co., Inc.
Weill Cornell Medicine receives $3.4 million NIH grant to study type 1 diabetes development